Dr. Narayana Rao
Breast cancers often produce tumor marker CA15.3 which can be estimated through immunoassays available commercially. So, the aim of this study is to asses the clinical utility of this tumor marker test for daily practice. The utility of measuring CA15-3 levels for breast cancer patients remains controversial. The ASCO and the NCCN guidelines do not currently recommend the use of serum CA15-3 for breast cancer screening and directing treatment post-operative surveillance Metastatic disease (ASCO, NCCN, EGTM, ESMO) and monitoring treatment response. There were limitations to utility in clinical practice. Further prospective studies will be essential for the validation of these results in our own clinical setting.
Pages: 01-05 | 67 Views 23 Downloads